Overview

A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer

Status:
Completed

Trial end date:
2020-03-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Cascadian Therapeutics Inc.
Seagen Inc.

Treatments:

Capecitabine
Trastuzumab
Tucatinib